NBIX - Neurocrine nabs FDA label expansion for Ingrezza
2023-08-18 17:35:35 ET
More on Neurocrine
- Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Efforts
- Neurocrine Biosciences, Inc. ( NBIX ) Q2 2023 Earnings Call Transcript
- Neurocrine Biosciences: In Limbo Until The Arrival Of The 'Next Big Thing' Beyond Ingrezza
- BMO upgrades Neurocrine to market perform on Ingrezza outlook
- Seeking Alpha’s Quant Rating on Neurocrine Biosciences
For further details see:
Neurocrine nabs FDA label expansion for Ingrezza